Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
AI microprocessor on motherboard computer circuit, Artificial intelligence integrated inside Central Processors Unit or CPU chip, 3d rendering futuristic digital data technology concept background

YFM and Maven lead £6.5m Series A into Deep Tech AI company, Biorelate

Manchester-based biotech innovator to use capital to fund its product, sales and marketing departments, and establish an operation in the US

Maven Capital Partners (“Maven”) and YFM Equity Partners (“YFM”), have announced the completion of a £6.5m Series A investment for Biorelate.

Founded in 2014 and led by Daniel Jamieson, Biorelate curates dark biomedical knowledge to empower drug discovery with its proprietary AI platform, Galactic AI™. Galactic AI’s innovative technology uniquely combines natural language processing (NLP) and machine learning (ML) to capture highly valuable biomedical data that pharmaceutical and life sciences organisations can utilise to improve decision making in their drug discovery programs.

As drug discovery becomes increasingly more difficult to turn a profit, biopharmaceutical companies are investing more into AI and data-driven solutions that improve the chances of success. These same approaches can also be instrumental in finding entirely new hypotheses unforeseen by human experts. Biorelate are helping on both fronts by capturing billions of biomedical datapoints not found in existing databases, that they use to form a more complete map of scientific research. They then use this to support biopharma companies with target, biomarker and other related drug discovery challenges. Since launching Galactic AI™ in 2020, Biorelate has experienced significant growth and has brought on board leading global companies such as AstraZeneca and Idorsia, as well as a host of other undisclosed names.

The funding was raised through YFM’s VCTs, the Maven VCTs and Triple Point Ventures, with continued investment from NPIF – Maven Equity Finance, which is managed by Maven and part of the Northern Powerhouse Investment Fund, as well as a group of angel investors from the Manchester Tech Trust. Biorelate will use the investment to increase its commercial and technical capacity, as well as wider expansion into the US to tap into the industry’s largest market.

Gavin Bell, Investment Director led the deal for Maven. The YFM team included Andy Thomas, Aaron Lowery and Ian Waterfield.

Dan Jamieson, founder and CEO of Biorelate, said: ”Drug discovery is so exciting right now, as there are just so many incredible companies working on remarkable new therapeutics. Equally, we are at a time where there is a stupendous amount of untapped evidence, like cause-and-effect, sat dark and subsequently unused by these same companies. Our mission at Biorelate is to capture this untapped data and help them make sense of it. With this improved understanding we are empowering these companies to make better decisions and speed up the drug discovery process.”

Gavin Bell, Investment Director at Maven, said: “Biorelate has grown significantly since we first backed the business at an early stage through NPIF Maven Equity Finance. It’s exciting to see an innovative deep tech business born in Manchester now develop globally. We’re absolutely delighted to continue to support the vision and ambition of Dan and the Biorelate team, to scale and capitalise on the attractive global growth opportunities.”

Andy Thomas, Partner at YFM Equity Partners, said: “By quickly and effectively processing the growing and evolving swathe of publicly available biomedical data, Biorelate has the ability to be at the forefront of innovation in the pharmaceutical and life sciences industry. We are excited to be part of the next step in the business’ journey, and see huge potential for continued growth and expansion.”

Sean Hutchinson at the British Business Bank, said: “We are pleased that the Northern Powerhouse Investment Fund is continuing to unlock the North’s growth potential through ambitious businesses like Biorelate, that make profound differences in their industries. Biorelate’s growth is a step forward for the pharmaceutical and life sciences industry, and NPIF is proud to have facilitated its development.”

Other advisers on the deal included: Craig Corporate, Sales Blueprint, Pannone Corporate, The Startup Factory, Catalysis, Lockton, Shoosmiths, Philip Hare & Associates, CMS and Hadley Appenine.